Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
480 participants
OBSERVATIONAL
2023-08-31
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SUBLOCADE Rapid Initiation Extension Study
NCT04060654
Evaluating the SUBLOCADE Treatment Exit Strategy
NCT05878210
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
NCT05704543
Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder
NCT05594121
Evaluation of Long-term Buprenorphine Plasma Exposure
NCT03752528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Is an adult ≥ 18 years of age who has signed the informed consent form
* Plans to receive additional SUBLOCADE injections and
* Has initiated treatment for OUD/opioid dependence with SUBLOCADE within the last 3 months prior to Baseline Visit
* OR
* Has completed an Indivior SUBLOCADE study (eg, INDV-6000-401, INDV-6000-405) and has received the last dose of SUBLOCADE on that study within 3 months prior to Baseline Visit
* Is not currently participating in any clinical trial requiring medical intervention
* Is not currently using opioids to treat a diagnosis other than OUD/opioid dependence
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indivior Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ATP Clinical Research
Costa Mesa, California, United States
Neighborhood Healthcare-Institute of Health
Escondido, California, United States
Elevate Health and Wellness
Westport, Connecticut, United States
United Research Institute
Hialeah, Florida, United States
Zenith Clinical Research LLC
Hollywood, Florida, United States
Jackson Health Community Center
Miami, Florida, United States
G+C Research Group
Miami, Florida, United States
Atlanta VA Medical Center
Decatur, Georgia, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Collective Medical Research.
Prairie Village, Kansas, United States
Maine Health
Scarborough, Maine, United States
Maryland Treatment Centers
Baltimore, Maryland, United States
Baystate Health
Springfield, Massachusetts, United States
THRYV Clinical Studies
Dearborn, Michigan, United States
Vida Clinical Studies
Dearborn Heights, Michigan, United States
Wayne State University Hospital
Detroit, Michigan, United States
North Point Medical Center
Fair Haven, Michigan, United States
SHMG Center for Integrative Medicine
Grand Rapids, Michigan, United States
North Mississippi Medical Center
Tupelo, Mississippi, United States
Psych Care Consultants
St Louis, Missouri, United States
DENT Neurologic Institute
Amherst, New York, United States
United Health Services
Binghamton, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Core Clinical Trials
North New Hyde Park, New York, United States
Stuart Wasser Practice
Rockville Centre, New York, United States
Onsite Clinical Solutions LLC
Charlotte, North Carolina, United States
Pahl Pharmaceutical Professionals LLC
Oklahoma City, Oklahoma, United States
Healing Comfort Clinic, LLC
Corvallis, Oregon, United States
Thalia Medical Centre
Narberth, Pennsylvania, United States
Charleston Pain and Rehabilitation Center
Charleston, South Carolina, United States
Midlands Neurology
Columbia, South Carolina, United States
Prisma Health
Greenville, South Carolina, United States
Biopharma Informatic, Inc. Research Center
Houston, Texas, United States
Alpine Research Organization
Clinton, Utah, United States
Virginia Commonwealth University
Richmond, Virginia, United States
St Vincent's Hospital Melbourne
Fitzroy, Melbourne, Australia
John Hunter Hospital
Newcastle, New South Wales, Australia
Drug and Alcohol Services South Australia (DASSA)
Stepney, South Australia, Australia
Turning Point
Richmond, , Australia
Smart Clinic
Calgary, Alberta, Canada
Recovery Alberta
Edmonton, Alberta, Canada
Fraser Health Authority
Surrey, British Columbia, Canada
Dr. J.S. Dhillon Medicine Prof. Corp
Burlington, Ontario, Canada
The Stipley Clinic
Hamilton, Ontario, Canada
Brightshores Health System
Owen Sound, Ontario, Canada
Bluewater Rapid Assessment Addiction Medicine Clinic
Sarnia, Ontario, Canada
Comprehensive Treatment Clinic
Toronto, Ontario, Canada
Linkoping University Hospital, Psychiatry Center
Linköping, , Sweden
Beroendecentrum
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INDV-6000-406
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.